HOME ·

R&D Progress

LEADS BIOLABS-B (09887.HK): NDA for Virexin as Treatment for Extrapulmonary Neuroendocrine Carcinoma Accepted by NMPA
Tags：
LEADS BIOLABS-B09887.HKR&D Progress
2026-08-21
CANSINOBIO (06185.HK): Tetanus Vaccine Receives NMPA New Drug Application Approval, Expanding Adult Vaccine Market
Tags：
CANSINOBIO06185.HKR&D Progress
2026-08-20
HENGRUI PHARMA (01276.HK): SHR-7012 Injection Receives Clinical Trial Approval for Treating Cutaneous Lupus Erythematosus
Tags：
HENGRUI PHARMA01276.HKR&D Progress
2026-08-20
ALPHAMAB-B (09966.HK): NDA for Anbenitamab Combination as First-Line Treatment for HER2-Positive Advanced Breast Cancer Accepted by NMPA
Tags：
ALPHAMAB-B09966.HKR&D Progress
2026-08-18
CSPC PHARMA (01093.HK): NDA for KN026 Plus HB1801 as First-Line Treatment for Advanced Breast Cancer Accepted by NMPA
Tags：
CSPC PHARMA01093.HKR&D Progress
2026-08-18
CANBRIDGE-B (01228.HK): Maralixibat Oral Solution Approved for NHI Reimbursement in Taiwan, China, Effective 1 September
Tags：
CANBRIDGE-B01228.HKR&D Progress
2026-08-18
AKESO (09926.HK): NMPA Approves Third Indication of Ivonescimab (PD-1/VEGF) for First-Line Treatment of Advanced Squamous NSCLC
Tags：
AKESO09926.HKR&D Progress
2026-08-13
UNISOUND (09678.HK): Self-Developed Medical Imaging Multimodal Large Model U2-RadiMed Officially Released, Ranking First in Comprehensive Benchmarks
Tags：
UNISOUND09678.HKR&D ProgressHealthcare AI
2026-08-13
HENGRUI PHARMA (01276.HK): SHR-7590 Injection Receives Drug Clinical Trial Approval Notice for Ulcerative Colitis and Crohn's Disease
Tags：
HENGRUI PHARMA01276.HKR&D Progress
2026-08-12
HENGRUI PHARMA (01276.HK): HRS-4729 Injection Approved for Phase II Clinical Trial in Type 2 Diabetes
Tags：
HENGRUI PHARMA01276.HKR&D Progress
2026-08-12
IMPACT THERAP-B (07630.HK): Nominates IMP2794 as preclinical candidate compound, first KAT6A-specific PROTAC from self-owned targeted protein degradation platform
Tags：
IMPACT THERAP-B07630.HKR&D Progress
2026-08-12
LAEKNA-B (02105.HK): NDA for LAE002 (Afuresertib) Accepted by NMPA for HR+/HER2- Breast Cancer
Tags：
LAEKNA-B02105.HKR&D Progress
2026-08-12
MICOT PHARMA-B (02335.HK): Preclinical and Phase I data of neuroprotective candidate MT200605 accepted for oral presentation at 2026 World Stroke Congress; Phase II meets primary endpoint
Tags：
Micot Pharma-B02335.HKR&D Progress
2026-08-11
KEYMED BIO-B (02162.HK): Phase II trial of CM512 (TSLP x IL-13 bispecific antibody) for chronic rhinosinusitis with nasal polyps meets all study endpoints; Phase III to advance with 300mg once-half-yearly regimen
Tags：
KEYMED BIO-B02162.HKR&D Progress
2026-08-10
GENFLEET-B (02595.HK): Phase III study of world's first oral KRAS G12D inhibitor for NSCLC initiated; second registrational clinical study of GFH375 completes first patient enrolment
Tags：
GENFLEET-B02595.HKR&D Progress
2026-08-10
GRANDPHARMA (00512.HK): Innovative RDC Drug GPN01530-2 Granted FDA Fast Track Designation for Diagnosis of Solid Tumors
Tags：
GRANDPHARMA00512.HKR&D Progress
2026-08-09
LUZHU BIOTECH-B (02480.HK): Phase III Results of Shingles Vaccine LZ901 Published in Nature Communications, Overall Vaccine Efficacy of 91.6%
Tags：
LUZHU BIOTECH-B02480.HKR&D Progress
2026-08-09
SBP GROUP (01177.HK): New Indication of Benmelstobart plus Chemotherapy Sequentially with Anlotinib as First-Line Treatment for Squamous NSCLC Approved for Marketing
Tags：
SBP GROUP01177.HKR&D Progress
2026-08-07
EDDING GENOR (06998.HK): First subject dosed in Phase Ib/II trial of trispecific antibody GB268 for breast cancer
Tags：
EDDING GENOR06998.HKR&D Progress
2026-08-07
CARSGEN-B (02171.HK): Universal CAR-T product CT1190B receives NMPA IND approval for treatment of relapsed/refractory large B-cell lymphoma
Tags：
CARSGEN-B02171.HKR&D Progress
2026-08-07
Previous123 4